First Time Loading...

Verastem Inc
NASDAQ:VSTM

Watchlist Manager
Verastem Inc Logo
Verastem Inc
NASDAQ:VSTM
Watchlist
Price: 11.82 USD 1.98%
Updated: Mar 28, 2024

Intrinsic Value

VSTM's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. [ Read More ]

The intrinsic value of one VSTM stock under the Base Case scenario is 9.43 USD. Compared to the current market price of 11.82 USD, Verastem Inc is Overvalued by 20%.

Key Points:
VSTM Intrinsic Value
Base Case
9.43 USD
Overvaluation 20%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Verastem Inc

Backtest VSTM Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VSTM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Verastem Inc

Current Assets 143.7m
Cash & Short-Term Investments 137.1m
Other Current Assets 6.6m
Non-Current Assets 6m
PP&E 1.2m
Other Non-Current Assets 4.8m
Current Liabilities 26.4m
Accounts Payable 7.2m
Accrued Liabilities 18.9m
Other Current Liabilities 327k
Non-Current Liabilities 44.8m
Long-Term Debt 40.1m
Other Non-Current Liabilities 4.7m
Efficiency

Earnings Waterfall
Verastem Inc

Revenue
0 USD
Operating Expenses
-92.1m USD
Operating Income
-92.1m USD
Other Expenses
4.7m USD
Net Income
-87.4m USD

Free Cash Flow Analysis
Verastem Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

VSTM Profitability Score
Profitability Due Diligence

Verastem Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

Verastem Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

VSTM Solvency Score
Solvency Due Diligence

Verastem Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
47/100
Solvency
Score

Verastem Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VSTM Price Targets Summary
Verastem Inc

Wall Street analysts forecast VSTM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VSTM is 29.36 USD with a low forecast of 17.68 USD and a high forecast of 37.8 USD.

Lowest
Price Target
17.68 USD
50% Upside
Average
Price Target
29.36 USD
148% Upside
Highest
Price Target
37.8 USD
220% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

VSTM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

VSTM Price
Verastem Inc

1M 1M
-8%
6M 6M
+42%
1Y 1Y
+135%
3Y 3Y
-56%
5Y 5Y
-66%
10Y 10Y
-90%
Annual Price Range
11.82
52w Low
4.2
52w High
14.07
Price Metrics
Average Annual Return -18.45%
Standard Deviation of Annual Returns 64.1%
Max Drawdown -94%
Shares Statistics
Market Capitalization 298.8m USD
Shares Outstanding 25 268 100
Percentage of Shares Shorted 3.04%

VSTM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Verastem Inc Logo
Verastem Inc

Country

United States of America

Industry

Biotechnology

Market Cap

298.8m USD

Dividend Yield

0%

Description

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.

Contact

MASSACHUSETTS
Needham
117 Kendrick St Ste 500
+17812924200.0
http://www.verastem.com/

IPO

2011-11-08

Employees

48

Officers

President, CEO & Director
Mr. Daniel W. Paterson
CFO, Head of Investor Relations, Principal Accounting Officer & Financial Officer
Mr. Daniel Calkins
Founder and Consultant
Mr. Richard H. Aldrich M.B.A.
Co-Founder & Chair of Scientific Advisory Board
Dr. Robert A. Weinberg Ph.D.
Co-Founder
Dr. Michelle Dipp M.D., Ph.D.
Senior Vice President of Technical Operations
Mr. Robert Pintar M.B.A.
Show More
Chief Scientific Officer
Dr. Jonathan Pachter Ph.D.
Senior Vice President of Corporate Development & External Engagement
Mr. Nate Sanburn
Head of Medical Strategy
Dr. Hagop Youssoufian M.D., M.Sc., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one VSTM stock?

The intrinsic value of one VSTM stock under the Base Case scenario is 9.43 USD.

Is VSTM stock undervalued or overvalued?

Compared to the current market price of 11.82 USD, Verastem Inc is Overvalued by 20%.